BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
BioXcel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026
- Market cap
- $757.50K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
74.5%
Operating margin
-7860.0%
Net margin
-10887.4%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -71.7% | +19.6% | – | – | |
| Gross profit | +288.6% | +10.4% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -70.4% | 74.1% | |
| Return on assets | – | -64.1% | -167.9% | |
| Current ratio | – | 18.33 | 0.83 | |
| Debt to equity | – | – | -1.15 | |
| Interest coverage | – | -3048.0× | -3.0× | |
| Inventory turnover | – | – | 0.2× | |
| Capex to revenue | – | – | 0.0% | |
| Diluted shares | – | 1M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
BioXcel Therapeutics generated $502.14M from operations and spent $604.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$502.14M
Used
$604.00K
Capital expenditure$604.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-10887.4%
×Asset turnover0.02×
×Equity multiplier-0.44×
=Return on equity, FY202574.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -10887.4% | 0.02× | -0.44× | 74.1% |
| FY2024 | -2630.1% | 0.04× | -0.75× | 79.7% |
| FY2023 | -12974.9% | 0.01× | 13.79× | -1766.9% |
| FY2022 | -44201.9% | 0.00× | 1.49× | -111.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$69.90M
- Cash generatingOperating cash flow above zero-$57.62M
- Return on assets improvedROA up on the prior year-80.9% → -182.3%
- Earnings backed by cashOperating cash flow above net income-$57.62M vs -$69.90M
- Less leverageLong-term debt to assets fell267.4% → 188.5%
- Better liquidityCurrent ratio rose1.68 → 0.83
- No dilutionShare count did not rise3M → 12M
- Gross margin improvedGross margin up on the prior year5.43% → 74.45%
- More efficientAsset turnover rose0.03 → 0.02